A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...

Podrobná bibliografie
Hlavní autoři:	Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
Médium:	Článek
Jazyk:	English
Vydáno:	SAGE Publishing 2022-09-01
Edice:	Cancer Control
On-line přístup:	https://doi.org/10.1177/10732748221130576

Podobné jednotky

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
Autor: Hiroki Hata MS, a další
Vydáno: (2020-12-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
Autor: Hideo Oishi, MD, a další
Vydáno: (2020-10-01)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
Autor: Arthur E. Frankel MD, a další
Vydáno: (2019-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
Autor: Taichi Miyawaki, MD, a další
Vydáno: (2020-06-01)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
Autor: Bilguun Erkhem-Ochir, MD, a další
Vydáno: (2021-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
Autor: Samit Chatterjee PhD, a další
Vydáno: (2017-07-01)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
Autor: Tara Davidson, MD, a další
Vydáno: (2022-07-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
Autor: Chenxing Zhang, PhD, a další
Vydáno: (2020-03-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
Autor: Daisuke Hazama, MD, PhD, a další
Vydáno: (2024-01-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
Autor: Tatsuya Nishikawa, MD, PhD, a další
Vydáno: (2022-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
Autor: Kenji Morimoto, MD, PhD, a další
Vydáno: (2022-09-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
Autor: Mariana Mirabel, MD, PhD, a další
Vydáno: (2020-09-01)

A Modified Method for the Quantification of Immune Checkpoint Ligands on Exosomes from Human Serum using Flow Cytometry
Autor: Alan Guillermo Alejandre Gonzalez PhD, a další
Vydáno: (2023-05-01)

A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8
Autor: Amanda Leiter, MD, MSCR, a další
Vydáno: (2020-07-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
Autor: Yasunori Murata, MD, PhD, a další
Vydáno: (2023-12-01)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
Autor: Fatih Kus MD, a další
Vydáno: (2024-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
Autor: Shiting Xu, MD, a další
Vydáno: (2022-04-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
Autor: Yuto Terashima, MD, a další
Vydáno: (2023-11-01)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
Autor: Xinlun Dai MD, a další
Vydáno: (2020-08-01)

Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
Autor: Lianghui Zhang MS, a další
Vydáno: (2024-08-01)

A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
Autor: Mahdieh Azizi, PhD, a další
Vydáno: (2024-01-01)

Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma
Autor: Qiang Liu PhD, a další
Vydáno: (2024-04-01)

Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes
Autor: Etienne Charpentier, MD, a další
Vydáno: (2024-01-01)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
Autor: Jack M. Qian, MD, a další
Vydáno: (2022-03-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
Autor: Mandy Jongbloed, MD, a další
Vydáno: (2025-03-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
Autor: Dorothy M. Gujral, PhD, a další
Vydáno: (2020-02-01)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
Autor: Ying Teng PhD, a další
Vydáno: (2022-03-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
Autor: Tristan V.M. Bruijn, MD, a další
Vydáno: (2024-05-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
Autor: Kana Hashimoto, MD, a další
Vydáno: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
Autor: Natalie Bourand, MS, a další
Vydáno: (2025-02-01)

Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo
Autor: Hsin-Ling Yang PhD, a další
Vydáno: (2017-09-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
Autor: Roger Y. Kim, MD, a další
Vydáno: (2021-06-01)

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
Autor: Benjamin M.P. Elyan, MBChB, a další
Vydáno: (2023-07-01)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
Autor: Marco Tagliamento, MD, a další
Vydáno: (2023-01-01)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
Autor: Denis L. Jardim MD, PhD, a další
Vydáno: (2018-12-01)

Seeking “protective” and “harmful” immune genes during chronic HIV-1 infection by transcriptome analysis
Autor: Lingyan Zhu, PhD, a další
Vydáno: (2018-09-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
Autor: Alicia Quilez, MD, a další
Vydáno: (2020-03-01)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation
Autor: Jia-Jun Wu, MD, a další
Vydáno: (2022-06-01)

The Value of Combined Detection of Megakaryocyte and Platelet Parameters for the Diagnosis of Primary Immune Thrombocytopenia
Autor: Weiwei Wang MS, a další
Vydáno: (2022-08-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
Autor: Sakeena Fatima, BA, a další
Vydáno: (2018-04-01)